• Expanding commercialisation presence with multiple regional partners and direct US salespeople
• Positive NervAlign Nerve Cuff clinical study results, company revenue up 53% year-on-year
• Targeting $6.19 billion global nerve repair biomaterials market by 2031

ReNerve is an ASX-listed medical device company developing a comprehensive portfolio of products for the nerve repair and regeneration markets. Over the past 12 months, the company has completed an IPO, established multiple regional partnerships in the Middle East, Mexico, India, and Hong Kong, and added direct salespeople in the US, now with 21 distribution partners. The company has also seen positive results from a clinical study on its NervAlign Nerve Cuff and reported a 53% year-on-year increase in revenue. ReNerve's product portfolio includes nerve cuffs, tubes, protectors, and a nerve guide matrix, targeting applications in trauma, plastic surgery, orthopedics, and other areas. The global nerve repair biomaterials market is projected to grow at a CAGR of 17.8% from 2024 to 2031, reaching $6.19 billion. ReNerve is focused on expanding its presence in the US and globally, with upcoming product launches, clinical data, and regulatory approvals in key markets.

ReNerve is focused on driving sales and launching new products into the market, with a fourth product expected to come to market soon. The company is also working to gain more customer approvals, expand its distribution network, and leverage positive clinical data to drive global expansion. The 'Align' study on the NervAlign Nerve Cuff is ongoing, with initial data expected in 2026.